national stem-cell therapy logo

Stem Cells: Revolutionizing Autoimmune Treatment with Kyverna & ElevateBio

Help Spread The Word, Share Post:

Kyverna Therapeutics, a clinical-stage cell therapy company, and ElevateBio, a technology-driven company specializing in cell and gene therapies, have announced a partnership aimed at advancing the development and manufacturing processes for Kyverna’s Ingenui-T-derived chimeric antigen receptor (CAR) T-cell therapies.

The Ingenui-T platform, developed by Kyverna, is optimized for autologous CAR-T cell manufacturing for autoimmune diseases, aiming to lower costs and improve patient experiences.

Key Developments:

  • Kyverna will leverage ElevateBio BaseCamp’s expertise in process development and cell product manufacturing to achieve a lower cost of goods.
  • The partnership will integrate Kyverna’s Ingenui-T platform into ElevateBio BaseCamp’s process development and manufacturing efforts, aiming to produce industry-leading CAR T-cell therapies.
  • Kyverna is focusing on revolutionizing treatments for patients with autoimmune diseases by building on the learnings from CAR T-cell therapy in oncology.
  • ElevateBio combines multiple next-generation technology platforms with industry-leading expertise to transform the current cell and gene therapy development paradigm.

Details about Ingenui-T and KYV-101:

  • Ingenui-T is Kyverna’s proprietary cost-efficient autologous CAR T-cell therapy manufacturing process, designed specifically to meet the needs of autoimmune disease patients.
  • KYV-101 is an autologous version of a novel, fully human clinical-stage anti-CD19 chimeric antigen receptor (CAR) T-cell construct, well suited for use in B cell-driven autoimmune diseases like lupus nephritis.

About Kyverna Therapeutics and ElevateBio:

  • Kyverna Therapeutics is on a mission to engineer a new class of therapies for autoimmune and inflammatory diseases, combining advanced T-cell engineering and synthetic biology technologies.
  • ElevateBio is built to power the development of transformative cell and gene therapies, offering turnkey scale and biotechnological capabilities to power cell and gene therapy processes, programs, and companies to their full potential.

For more info:

*** All content on is for informational purposes only. All medical questions and concerns should always be consulted with your licensed healthcare provider.

Stay Connected

More Updates